SBP GROUP(01177),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01177 SBP GROUP

Market Closed 05-15 16:09:05

5.390

-0.200

-3.58%

High5.570	Low5.340	Vol88.11M
Open5.570	D1 Closing5.590	Amplitude4.11%
Mkt Cap101.04B	Tradable Cap101.04B	Total Shares18.75B
T/O475.19M	T/O Rate0.47%	Tradable Shares18.75B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"SBP GROUP","latestPrice":5.39,"timestamp":1778832545002,"preClose":5.59,"halted":0,"volume":88108321,"delay":0,"changeRate":-0.03577817531305907,"floatShares":18745000000,"shares":18745000000,"eps":0.14915648025403885,"marketStatus":"Market Closed","change":-0.2,"latestTime":"05-15 16:09:05","open":5.57,"high":5.57,"low":5.34,"amount":475187941,"amplitude":0.041145,"askPrice":5.39,"askSize":822000,"bidPrice":5.38,"bidSize":375000,"shortable":3,"etf":0,"ttmEps":0.14915648025403885,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":7,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.59,"dividendRate":0.016698,"openAndCloseTimeList":[[1778808600000,1778817600000],[1778821200000,1778832000000]],"volumeRatio":1.101635,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.4017,"impliedVolPercentile":0.3927},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"1103791679","title":"SBP GROUP logs HK$10.03 million buyback; 32.70 million shares awaiting cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=1103791679","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103791679?lang=en_us&edition=fundamental","pubTime":"2026-05-15 16:44","pubTimestamp":1778834646,"startTime":"0","endTime":"0","summary":"SBP GROUP (formerly Sino Biopharmaceutical Limited) disclosed that it repurchased 1.87 million ordinary shares on 15 May 2026 via the Hong Kong Stock Exchange. • Repurchase specifics    – Volume:...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148699927","title":"SBP GROUP (01177) Allocates HK$10.03 Million for Share Buyback on May 15","url":"https://stock-news.laohu8.com/highlight/detail?id=1148699927","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148699927?lang=en_us&edition=fundamental","pubTime":"2026-05-15 16:40","pubTimestamp":1778834417,"startTime":"0","endTime":"0","summary":"SBP GROUP (01177) announced the repurchase of 1.87 million shares on May 15, 2026, with a total expenditure of HK$10.03 million.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","BK1521","01177","BK1191","BK1589","BK1515","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635704616","title":"Sino Biopharmaceutical Stock Slides 3.6% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2635704616","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635704616?lang=en_us&edition=fundamental","pubTime":"2026-05-15 16:31","pubTimestamp":1778833860,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. shed 3.6% to 5.39 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.6% to 25962.73.This was the stock's third consecutive day of losses.Sino Biopharmaceutical Ltd. closed 41% short of its 52-week high of HK$9.12, which the company reached Sept. 10.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. fell 2.3% and Amgen Inc. remained unchanged.Trading volume totaled 88.1 million shares, compared to the 50-day average of 75.0 million shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE00B4R5TH58.HKD","IE00BZ08YR35.GBP","LU0122379950.USD","LU1023059063.AUD","BK1515","LU0868494617.USD","LU2468319806.SGD","LU2242646821.SGD","LU2112291526.USD","IE00BZ08YS42.EUR","BK4588","HK0000165453.HKD","01177","IE0009355771.USD","IE00B2B36J28.USD","BK1191","LU2242652126.USD","BK1589","BK4533","IE00BFTCPJ56.SGD","BK4139","LU1571399168.USD","IE00BZ08YT58.USD","BK1521","BK4566","LU1057294990.SGD","SG9999001440.SGD","LU2089984988.USD","BK4534","BK4585","LU1983299246.USD","LU0058720904.USD","LU0109394709.USD","AMGN","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0289739699.SGD","IE0002141913.USD","BK4599","LU1061106388.HKD","BK4581","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140124345","title":"SBP GROUP (01177) Repurchases 1.82 Million Shares for HK$10.04 Million on May 14","url":"https://stock-news.laohu8.com/highlight/detail?id=1140124345","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140124345?lang=en_us&edition=fundamental","pubTime":"2026-05-14 16:40","pubTimestamp":1778748025,"startTime":"0","endTime":"0","summary":"SBP GROUP (01177) announced that on May 14, 2026, the company repurchased 1.82 million shares for a total consideration of HK$10.04 million. The repurchase price per share ranged from HK$5.51 to HK$5.52.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","BK1589","01177","BK1191","IE00BZ08YT58.USD","BK1521","BK1515","IE00BZ08YS42.EUR","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161568352","title":"SBP GROUP (01177) Unveils Preclinical Findings for Novel Drug TQF6422 at 2026 European Congress on Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=1161568352","media":"Stock News","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161568352?lang=en_us&edition=fundamental","pubTime":"2026-05-14 06:50","pubTimestamp":1778712614,"startTime":"0","endTime":"0","summary":"SBP GROUP (01177) announced that preclinical research data for the innovative drug TQF6422, an \"ActRII A/B monoclonal antibody,\" independently developed by its subsidiary Chia Tai Tianqing...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","BK1191","BK1515","BK1589","IE00BZ08YS42.EUR","BK4144","IE00BZ08YR35.GBP","LU0997586861.USD","HK0000165453.HKD","ECO","IE00BZ08YT58.USD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635511197","title":"Sino Biopharm says preclinical data show TQF6422 boosts fat loss, preserves lean mass","url":"https://stock-news.laohu8.com/highlight/detail?id=2635511197","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635511197?lang=en_us&edition=fundamental","pubTime":"2026-05-14 06:16","pubTimestamp":1778710596,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical disclosed preclinical results for obesity candidate TQF6422, a fully human ActRII A/B monoclonal antibody, presented at European Congress on Obesity 2026.Studies showed more than 10x higher in vitro activity versus comparable products, with stronger fat-loss effects and lean-mass preservation across multiple animal models at lower doses.In an obese monkey model, combination with semaglutide increased fat reduction by 1.5-2x versus semaglutide alone, lifted lean-mass retention by 72%-85%, with fat accounting for 93% of total weight loss.Drug half-life was described as meaningfully extended to support longer dosing intervals, with no drug-related adverse reactions observed across tested doses in animals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL6DVgZz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","BK1589","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1521","IE00BZ08YR35.GBP","01177","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140556045","title":"SBP GROUP (01177) Executes HK$10.052 Million Share Buyback on May 13","url":"https://stock-news.laohu8.com/highlight/detail?id=1140556045","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140556045?lang=en_us&edition=fundamental","pubTime":"2026-05-13 16:38","pubTimestamp":1778661497,"startTime":"0","endTime":"0","summary":"SBP GROUP (01177) has announced the execution of a share repurchase. On May 13, 2026, the company utilized HK$10.052 million to buy back 1.78 million of its own shares.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","BK1589","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1521","IE00BZ08YR35.GBP","01177","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635473240","title":"Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After New GSK Partnership On Hepatitis B Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635473240","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635473240?lang=en_us&edition=fundamental","pubTime":"2026-05-13 02:49","pubTimestamp":1778611767,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical (SEHK:1177) has drawn fresh investor attention after subsidiary Chia Tai Tianqing agreed an exclusive partnership with GSK to commercialise bepirovirsen for chronic hepatitis B in mainland China.\nSee our latest analysis for Sino Biopharmaceutical.\nThe partnership news lands after a mixed price run, with the stock up 2.12% on a 1 day share price return and 6.25% over 7 days, yet down 15.37% over 90 days. The 1 year total shareholder return of 52.60% contrasts with weaker...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/assessing-sino-biopharmaceutical-sehk1177-valuation-after-ne","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/assessing-sino-biopharmaceutical-sehk1177-valuation-after-ne","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BZ08YR35.GBP","HK0000165453.HKD","BK4532","IE00BZ08YS42.EUR","DCF","BK4585","GSKH","BK4588","01177","GSK","BK1515","BK1191","BK4007","IE00BZ08YT58.USD","GSK.UK","BK1521","LU1829250122.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634960662","title":"Sino Biopharmaceutical Stock Rises 2.1% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2634960662","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634960662?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:32","pubTimestamp":1778574720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. rallied 2.1% to 5.78 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.2% to 26347.91.This was the stock's second consecutive day of gains.Sino Biopharmaceutical Ltd. closed 37% below its 52-week high of HK$9.12, which the company achieved Sept. 10.The stock outperformed some of its competitors, as CSPC Pharmaceutical Group Ltd. fell 1.1% and Amgen Inc. remained unchanged.Trading volume totaled 118.8 million shares, compared to the 50-day average of 75.1 million shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1057294990.SGD","SG9999001440.SGD","BK4599","LU1061106388.HKD","IE00BZ08YS42.EUR","LU0058720904.USD","BK1589","BK4139","BK4534","IE00BZ08YR35.GBP","LU1571399168.USD","HK0000165453.HKD","LU0109394709.USD","LU1983299246.USD","IE00B4R5TH58.HKD","BK4566","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU0889565916.HKD","BK1191","BK4533","LU0868494617.USD","BK1515","BK4585","IE00BJT1NW94.SGD","LU2089984988.USD","LU2242652126.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU0122379950.USD","BK1521","IE0009355771.USD","LU0320765992.SGD","BK4581","LU2242646821.SGD","IE0002141913.USD","AMGN","LU2112291526.USD","01177","LU2468319806.SGD","IE00BZ08YT58.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119185976","title":"SBP GROUP (01177) Rises Over 3% as Goldman Highlights Hepatitis Portfolio Enhancement with Bepirovirsen Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1119185976","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119185976?lang=en_us&edition=fundamental","pubTime":"2026-05-12 13:50","pubTimestamp":1778565023,"startTime":"0","endTime":"0","summary":"SBP GROUP (01177) saw an increase of over 3%. As of the latest update, the stock was up 2.65% to HK$5.81, with a turnover of HK$357 million. The catalyst stems from a recent Goldman Sachs research...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","LU2237443549.SGD","LU1668664300.SGD","LU2750360997.AUD","HK0000165453.HKD","IE00BFXG1179.USD","BK1515","LU0106831901.USD","LU0345770993.USD","BK4127","LU2265009873.SGD","BK4588","LU1791807156.HKD","LU1868837136.USD","IE0004086264.USD","BK4533","LU2237443622.USD","GSX","LU2237443895.HKD","LU2750360641.GBP","LU2237443978.SGD","LU2471134796.USD","LU0048573561.USD","LU2237443465.HKD","LU2471134952.CNY","IE0002270589.USD","BK4550","VXUS","LU2471134879.HKD","LU0742534661.SGD","GS","LU0251131958.USD","BK4552","IE00BZ08YT58.USD","IE00B19Z3581.USD","BK4516","LU0345770308.USD","LU0251142724.SGD","LU1804176565.USD","BK1191","LU1868837300.USD","LU2237438978.USD","LU1868836914.USD","LU0096364046.USD","LU1868836757.USD","IE00BZ08YS42.EUR","BK1521","BK1589","BK4504","IE0004091025.USD","01177","LU1868836591.USD","LU0061475181.USD","IE0034235188.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","BK4585","LU2471134523.USD","IE00BZ08YR35.GBP","LU2237443382.USD","LU1894683264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409962","title":"Hong Kong Stocks Little Changed as U.S.-Iran Talks Remain Deadlocked; LDROBOT Gains on Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409962","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634409962?lang=en_us&edition=fundamental","pubTime":"2026-05-11 16:38","pubTimestamp":1778488680,"startTime":"0","endTime":"0","summary":"Hong Kong stocks were broadly unchanged Monday as diplomatic tensions between the U.S. and Iran remained unresolved.The Hang Seng Index rose 13.13 points to end little changed at 26,406.84, while the Hang Seng China Enterprises Index barely moved in negative territory, slipping 4.87 points to finish at 8,884.20.U.S. President Donald Trump on Sunday rejected Iran's response to a U.S. proposal aimed at ending the conflict, calling Tehran's demands \"totally unacceptable.\"Iran's proposal centered on ending the conflict, lifting sanctions, securing reparations, and gaining recognition of its control over the Strait.Meanwhile, Trump and Chinese President Xi Jinping are expected to discuss Iran, Taiwan, artificial intelligence, and nuclear weapons as the two sides consider extending a critical minerals agreement during their first face-to-face meeting in more than six months.Trump is expected to arrive in Beijing on Wednesday ahead of talks scheduled for Thursday and Friday.In corporate news,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1589","SBHMY","02833","BK1191","HHImain","IE00BZ08YS42.EUR","BK1515","01236","IE00BZ08YT58.USD","BK1521","MCHmain","MHImain","HK0000165453.HKD","HSI","513600","IE00BZ08YR35.GBP","HSTECH","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409569","title":"Sino Biopharmaceutical Stock Climbs 4.2% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409569","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634409569?lang=en_us&edition=fundamental","pubTime":"2026-05-11 16:31","pubTimestamp":1778488260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. rallied 4.2% to 5.66 Hong Kong dollars , on what proved to be an all-around mediocre trading session for the Hong Kong stock market, with the Hang Seng Index remaining mostly flat at 26406.84.Sino Biopharmaceutical Ltd. closed 38% below its 52-week high of HK$9.12, which the company reached Sept. 10.The stock outperformed some of its competitors, as CSPC Pharmaceutical Group Ltd. remained unchanged and Amgen Inc. remained unchanged.Trading volume totaled 92.9 million shares, compared to the 50-day average of 75.1 million shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU1983299246.USD","AMGN","LU0122379950.USD","IE0009355771.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","IE00BFTCPJ56.SGD","BK4139","LU1023059063.AUD","LU2468319806.SGD","SG9999001440.SGD","BK1521","HK0000165453.HKD","LU0320765992.SGD","BK4566","LU0058720904.USD","LU1061106388.HKD","IE00BZ08YT58.USD","LU2242652126.USD","BK4588","LU0289739699.SGD","LU2112291526.USD","LU1057294990.SGD","BK4581","LU1571399168.USD","LU0868494617.USD","BK4599","IE00BJT1NW94.SGD","LU2242646821.SGD","BK4585","LU2089984988.USD","BK1589","BK1191","BK4533","BK1515","IE00B4R5TH58.HKD","LU0109394709.USD","IE0002141913.USD","LU0889565916.HKD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181393536","title":"SBP GROUP (01177) Repurchases 1.81 Million Shares for Approximately HK$10.01 Million on May 11","url":"https://stock-news.laohu8.com/highlight/detail?id=1181393536","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181393536?lang=en_us&edition=fundamental","pubTime":"2026-05-11 16:26","pubTimestamp":1778487990,"startTime":"0","endTime":"0","summary":"SBP GROUP (01177) announced that on May 11, 2026, the company repurchased 1.81 million shares at a total cost of approximately HK$10.01 million.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1191","BK1515","01177","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1521","IE00BZ08YR35.GBP","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634940620","title":"Sino Biopharm files HKEX return disclosing share buyback at HKD 5.53 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2634940620","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634940620?lang=en_us&edition=fundamental","pubTime":"2026-05-11 16:22","pubTimestamp":1778487735,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical repurchased 1,810,000 shares on May 11.Buyback executed at HKD 5.45 to HKD 5.58 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL4FzGwY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1191","BK1521","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YT58.USD","01177","IE00BZ08YR35.GBP","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634278477","title":"BUZZ-HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2634278477","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634278477?lang=en_us&edition=fundamental","pubTime":"2026-05-11 14:28","pubTimestamp":1778480893,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up** Shares of Sino Biopharmaceutical 1177.HK climb 4.2% to HK$5.66, their highest point since April 27** Stock set for the biggest one-day pct gain since April 15; top pct gainer in Hang Seng Biotech Index .HSBIO, which adds 0.8%** The Chinese pharmaceutical group said its unit Chia Tai Tianqing Pharmaceutical Group entered into an exclusive strategic collaboration with GlaxoSmithKline  to accelerate bepirovirsen, which is for treatment of chronic hepatitis B, in mainland China at launch** Says its unit will purchase bepirovirsen from GSK under agreed supply terms for an initial term of 5.5 years and will be responsible for importation, distribution, and hospital access of bepirovirsen in mainland China, while GSK will remain the marketing authorization holder ** YTD, stock down 8.7%, while benchmark Hang Seng Index .HSI up 3.1%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL1N41O05W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU0575583348.USD","LU0545562505.USD","LU1670756490.USD","IE0034235071.USD","LU1098665638.USD","LU1400636574.HKD","LU0971552830.HKD","IE00BWDBJ516.SGD","BK1191","LU1202635105.USD","LU0971552673.USD","BK1521","HK0000165453.HKD","LU1228905540.USD","LU0987226296.USD","GSK.UK","LU1035777561.USD","IE00BZ08YR35.GBP","LU1400636657.SGD","LU1015430645.USD","LU1481600234.SGD","IE00BQJZX424.USD","LU0203347892.USD","LU1983299246.USD","BK1589","BK1515","LU0225283273.USD","LU0557290698.USD","LU1309081286.SGD","SG9999001176.USD","LU1481599808.USD","LU1064927863.SGD","IE00B3T34201.USD","LU0321505868.SGD","LU0306807586.USD","LU0109981661.USD","LU1046248800.SGD","01177","LU0985481810.HKD","LU0211331839.USD","LU1228905037.USD","LU1487256676.USD","LU0306806265.USD","LU1645745479.HKD","LU2646069778.SGD","LU0225284248.USD","LU1302929846.USD","LU2468319806.SGD","BK5011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118145858","title":"SBP GROUP (01177) Surges Over 4% in Afternoon Session Following Hepatitis B Treatment Collaboration Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1118145858","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118145858?lang=en_us&edition=fundamental","pubTime":"2026-05-11 13:42","pubTimestamp":1778478148,"startTime":"0","endTime":"0","summary":"SBP GROUP (01177) saw its shares rise more than 4% in the afternoon trading session. At the time of writing, the stock was up 4.05% to HK$5.65, with a turnover of HK$278 million. The catalyst for the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1589","BK4532","BK1521","GSKH","IE00BZ08YS42.EUR","BK1191","BK1515","LU1829250122.USD","VXUS","GSK.UK","BK4007","BK4588","01177","BK4585","GSK","IE00BZ08YR35.GBP","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634713684","title":"Sino Biopharmaceutical to Distribute GSK's Hepatitis B Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2634713684","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634713684?lang=en_us&edition=fundamental","pubTime":"2026-05-11 12:40","pubTimestamp":1778474442,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical  secured a supply deal for GlaxoSmithKline's hepatitis B drug, bepirovirsen, for China, according to a Monday filing with the Hong Kong bourse.The firm's Chia Tai Tianqing Pharmaceutical Group entered into an exclusive strategic collaboration with GSK to cover the importation and distribution of bepirovirsen in mainland China for an initial term of 5.5 years at launch.Sino Biopharmaceutical's shares were up nearly 2% in midday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","GSK.UK","GSKH","HK0000165453.HKD","BK1589","01177","BK1515","IE00BZ08YR35.GBP","LU1829250122.USD","BK4007","GSK","IE00BZ08YT58.USD","BK4532","IE00BZ08YS42.EUR","BK4588","BK1191","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164732726","title":"SBP GROUP (01177) Enters Exclusive Strategic Partnership with GlaxoSmithKline PLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1164732726","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164732726?lang=en_us&edition=fundamental","pubTime":"2026-05-11 12:30","pubTimestamp":1778473831,"startTime":"0","endTime":"0","summary":"SBP GROUP (01177) has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has entered into an exclusive strategic collaboration with GlaxoSmithKline PLC (\"GSK\") to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","BK1191","BK1515","BK1589","GSK","BK4588","BK4532","GSKH","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1829250122.USD","HK0000165453.HKD","GSK.UK","BK4585","IE00BZ08YT58.USD","01177","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634947994","title":"Sino Biopharma unit CTTQ enters exclusive China bepirovirsen commercialization pact with GSK","url":"https://stock-news.laohu8.com/highlight/detail?id=2634947994","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634947994?lang=en_us&edition=fundamental","pubTime":"2026-05-11 12:10","pubTimestamp":1778472622,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical unit Chia Tai Tianqing entered exclusive strategic collaboration with GSK to support launch of hepatitis B drug bepirovirsen in mainland China.Chia Tai Tianqing to handle importation, distribution, hospital access, marketing activities; expects to recognize China sales revenue.GSK to remain marketing authorization holder; retains regulatory, quality, pharmacovigilance responsibilities.Initial term set at 5.5 years, with Chia Tai Tianqing purchasing supply from GSK under agreed terms; parties may extend by mutual agreement.Deal targets bepirovirsen, an investigational antisense therapy for chronic hepatitis B that entered NMPA priority review in April 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Bioph","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL3jCwc0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","BK1589","BK1515","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1191","BK1521","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634799174","title":"Sino Biopharmaceutical - Unit to Purchase Bepirovirsen From GSK Under 5.5-Year Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2634799174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634799174?lang=en_us&edition=fundamental","pubTime":"2026-05-11 12:10","pubTimestamp":1778472610,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41N00O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1589","BK1521","BK1191","HK0000165453.HKD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1515","01177"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.1264},{"period":"3month","weight":-0.1733},{"period":"6month","weight":-0.2657},{"period":"1year","weight":0.4011},{"period":"ytd","weight":-0.1278}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":0.0006},{"period":"3month","weight":-0.0227},{"period":"6month","weight":-0.0229},{"period":"1year","weight":0.107},{"period":"ytd","weight":0.013}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Sino Biopharmaceutical Ltd is an investment holding company mainly engaged in the pharmaceutical business. The Company operates its business through three segments. The Modernised Chinese Medicines and Chemical Medicines segment is mainly engaged in the manufacture, sale and distribution of modernised Chinese medicine products and western medicine products. The Investment segment is mainly engaged in the long term investments business. The Others segment is mainly engaged in the related healthcare and hospital business.","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.008254},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056687},{"month":3,"riseRate":0.565217,"avgChangeRate":0.045006},{"month":4,"riseRate":0.478261,"avgChangeRate":0.021296},{"month":5,"riseRate":0.695652,"avgChangeRate":0.041221},{"month":6,"riseRate":0.363636,"avgChangeRate":0.00957},{"month":7,"riseRate":0.636364,"avgChangeRate":0.047691},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010062},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.015174},{"month":10,"riseRate":0.545455,"avgChangeRate":0.025184},{"month":11,"riseRate":0.5,"avgChangeRate":0.066781},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.01175}],"exchange":"SEHK","name":"SBP GROUP","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SBP GROUP(01177),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SBP GROUP(01177) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SBP GROUP,01177,SBP GROUP股票,SBP GROUP股票老虎,SBP GROUP股票老虎国际,SBP GROUP行情,SBP GROUP股票行情,SBP GROUP股价,SBP GROUP股市,SBP GROUP股票价格,SBP GROUP股票交易,SBP GROUP股票购买,SBP GROUP股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SBP GROUP(01177),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SBP GROUP(01177) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}